GRI-0621; GRI-0803; Clinical Trials. IPF Trial; Investors. Overview; Press Releases; Events & Presentations; Stock Information; SEC Filings; Analyst Coverage; Corporate Governance; ...

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and …

GRI Bio (NASDAQ: GRI) is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s …

5 天之前 · About GRI. GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to …

3 天之前 · GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells. In preliminary trials to date and previous trials with the …

2 天之前 · GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a …

2 天之前 · GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a …

3 天之前 · GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a …

2023年8月23日 · GRI Bio（ 纳斯达克 股票代码：GRI）是一家临床阶段的 生物制药公司 ，致力于从根本上改变炎症、纤维化和自身免疫性疾病的治疗方式。 GRI Bio 的疗法旨在针对 NKT 细 …

GRI Bio (NASDAQ: GRI) is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s …